174 related articles for article (PubMed ID: 18376220)
1. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
4. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors.
Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S
Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
[TBL] [Abstract][Full Text] [Related]
7. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Xiang XJ; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
Chemotherapy; 2012; 58(1):1-7. PubMed ID: 22310723
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Dennie TW; Fleming RA; Bowen CJ; Dar MM; Alberti D; Oliver K; Loconte N; Mulkerin D; Holen KD
Clin Colorectal Cancer; 2011 Mar; 10(1):57-62. PubMed ID: 21609937
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
Shields AF; Zalupski MM; Marshall JL; Meropol NJ
Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial.
Hofheinz RD; Wenz F; Lukan N; Mai S; Kripp M; Staiger W; Schwarzbach M; Willeke F; Möhler M; Post S; Hochhaus A
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):142-7. PubMed ID: 18539404
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Dreicer R; Petrylak D; Agus D; Webb I; Roth B
Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Spigel DR; Burris HA; Shipley D; Farley C; Macias-Perez IM; Barton J; Greco FA
Cancer; 2010 May; 116(10):2448-54. PubMed ID: 20209610
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
Rödel C; Arnold D; Hipp M; Liersch T; Dellas K; Iesalnieks I; Hermann RM; Lordick F; Hinke A; Hohenberger W; Sauer R
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1081-6. PubMed ID: 17881150
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
[TBL] [Abstract][Full Text] [Related]
19. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Caponigro F; Lacombe D; Twelves C; Bauer J; Govaerts AS; Marréaud S; Milano A; Anthoney A
Eur J Cancer; 2009 Jan; 45(1):48-55. PubMed ID: 18809314
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
